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Purpose/Objective: When treated by radiotherapy, patients with 
squamous cell carcinomas of the head and neck (HNSCC) positive for 
HPV and p16 possess a clearly favorable prognosis as compared to 
those with HPV-negative HNSCC when the therapeutic regimens 
applied include radiotherapy. It was the aim of this work to study 
whether this phenomenon may be caused by an enhanced cellular 
radiosensitivity. 
Materials and Methods: The radiation response of five HPV and p16 
positive cell lines was compared to the response of five HPV and p16 
negative HNSCC strains. Cells were characterized with regard to 
cellular radiosensitivity, G1- and G2-arrest, apoptosis and residual 
DNA double strand breaks (DSB). Methods comprised the colony 
formation assay, the detection of PARP cleavage, the fluorescence-
based detection of caspase activity, propidium iodide staining, the 
colcemid-based G1-efflux assay and the immunofluorescence staining 
of gH2AX and 53BP1 foci. 
Results: On average, the cellular radiosensitivity of the five HNSCC 
cell lines positive for HPV and p16 was clearly enhanced when 
compared to the sensitivity of the HPV negative cells (SF3= 0.2827 vs. 
0.4455). This increase does not result from an increase in apoptosis or 
the execution of a permanent G1-arrest, but is rather associated with 
both, elevated levels of residual DSBs and extensive G2-arrest. 
Conclusions: Increased cellular radiosensitivity due to compromised 
DNA repair capacity is likely to contribute to the improved outcome of 
patients with HPV/p16 positive tumors when treated by radiotherapy. 
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Purpose/Objective: Following a successful national audit of static-
beam IMRT [1], a survey of 62 UK cancer centres in July 2010 
indicated that around 30% were treating with some form of rotational 
radiotherapy (RRT) (Varian RapidArc, Elekta VMAT or Helical 
Tomotherapy), and that this would increase to 50% by the end of 
2011. This rapid uptake led to the need for a national audit for RRT. 
We have previously investigated the use of a commercial detector 
array for national audit and developed a methodology for planning and 
measurement [2]. 
Materials and Methods: 30 UK cancer centres, who had already begun 
treating with RRT, took part in the audit and were visited between 
June 2011 - November 2012. This included 20 x Varian (17 Eclipse, 2 
OMP, 1 Pinnacle), 6 x Elekta (4 Monaco, 1 OMP, 1 Pinnacle), and 4 x 
Helical Tomotherapy. The UK IMRT credentialing program which 
covers RRT deliveries as well as static gantry IMRT delivery was used. 
This included a virtual phantom with 5 pre-created PTVs and one OAR, 
named the 3DTPS test [3], which all centres completed. Each centre 
also chose a clinical trial planning exercise (head and neck, pelvis or 
breast). Every centre was visited to make measurements on both plans 
using a PTW Octavius II phantom with the PTW seven29 2D Array. All 
verification plans were created on CT scans of the Octavius phantom 
with evaluations made using Verisoft. Global gamma index (γ) 
calculations were made using a 20% threshold, relative to a point in a 
high dose low gradient, and using absolute dose. Dose point 
differences were also calculated in regions corresponding to PTVs and 
OARs. 
Results: A total of 155 dose planes were measured and 283 point dose 
differences were calculated. For the 3DTPS test the percentage of 
planes achieving at least 95% of γ<1 were 45.7% (2%/2mm); 71.4% 
(3%/2mm); 88.6% (3%/3mm) and 100% (4%/4mm). The mean (sd) γ 
pass rates were: 93.2% (7.7%); 97.0% (4.7%); 98.7% (2.5%); 99.8% 
(0.7%) respectively. For the clinical plans the percentage of planes 
achieving at least 95% γ<1 were 62.5% (2%/2mm); 82.8% (3%/2mm); 
95.3% (3%/3mm) and 100% (4%/4mm). The mean (sd) γ pass rates 
were: 93.6% (6.8%); 97.5% (3.9%); 99.2% (1.5%); 99.9% (0.3%) 
respectively.  
Point dose differences for the 3DTPS test gave a mean of 0.2% (2.7%) 
for all points and a mean of 0.3% (2.0%) for PTVs only. For the clinical 
plans the mean difference was -0.4% (2.1%) and -0.3% (1.7%) for all 
points and PTV points respectively. The range of dose differences is 
shown in figure 1. 
  
Figure 1: Histograms of a) all clinical dose points & b) all 3DTPS plan 
points showing frequency of % difference between measured and TPS 
calculated dose points. 
 
Conclusions: A national audit of rotational radiotherapy has been 
undertaken in the UK. This has shown that more than 93% of analysed 
planes gave greater than 95% pass rates for gamma parameters of 
3%/3mm, thus achieving accurate implementation for TPS modelling 
and delivery for VMAT and Tomotherapy. 
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Radiation treatment comprises all the necessary steps from tumor 
diagnosis, multidisciplinary treatment decision, selection and 
delineation of tumor volumes (TV) and organs at risk (OAR), 
evaluation of dose distribution, and patient follow-up during and after 
completion of treatment. At each of these steps, the radiation 
oncologist has to manipulate images from various origins (e.g. CT-
scan, MRI, PET) and extract as much information as possible on the 
tumor extent, its biological profile, its response to therapy, not to 
mention that at the end of the day he will have to use his expertise to 
delineate TVs and OARs. 
But what is the biological meaning of an image and how reliable is it 
to depict the true tumor extent? Should images be used not only 
before but also during treatment to monitor tumor and normal tissue 
changes and allow for treatment individualization? What are the 
requirements to get meaningful images, how should one automatically 
extract information from various imaging modalities, and which 
processes should one put in place to streamline their use? 
All of these issues will be discussed during this Breur lecture, using 
head and heck tumors as a paradigm to try to illustrate that in 2013 
and beyond radiation oncology should be conformal, tailored and 
adaptive. 
 
 
 
 
 
 
